- Home
- NSRX vs DYAI Comparison
NSRX vs DYAI Comparison
Compare NSRX & DYAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NSRX | DYAI |
|---|---|---|
| Founded | 2019 | 1979 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.9M | 32.5M |
| IPO Year | 2024 | 2003 |
Fundamental Metrics
Financial Performance| Metric | NSRX | DYAI |
|---|---|---|
| Price | $4.10 | $0.61 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $19.67 | $3.00 |
| AVG Volume (30 Days) | 12.3K | ★ 150.9K |
| Earning Date | 03-25-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $3,090,345.00 |
| Revenue This Year | N/A | $122.79 |
| Revenue Next Year | N/A | $100.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.98 | $0.62 |
| 52 Week High | $9.50 | $1.60 |
Technical Indicators
Market Signals| Indicator | NSRX | DYAI |
|---|---|---|
| Relative Strength Index (RSI) | 64.61 | 29.73 |
| Support Level | $2.90 | N/A |
| Resistance Level | $4.49 | $0.90 |
| Average True Range (ATR) | 0.28 | 0.07 |
| MACD | 0.04 | -0.02 |
| Stochastic Oscillator | 89.52 | 2.14 |
Price Performance
Historical ComparisonAbout NSRX Nasus Pharma Ltd. Ordinary Shares
Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.
About DYAI Dyadic International Inc.
Dyadic International Inc is a biotechnology platform company. It has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.